期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子酪氨酸激酶抑制剂相关间质性肺炎临床分析 被引量：6

Clinical Analysis of Epidermal Growth Factor-Tyrosine Kinase Inhibitor Related Interstitial Lung Disease
原文传递
导出
摘要 [目的]探讨表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)相关间质性肺炎(ILD)的临床特点、危险因素、治疗和预后。[方法]总结北京协和医院肺癌中心4例EGFR-TKI相关ILD的临床特点,并进行相关文献复习。[结果]4例患者男女性各2例,均为腺癌,1例有肺纤维化的基础病,其中2例接受激素治疗的患者中1例有效,2例死于ILD。[结论]发生EGFR-TKI相关ILD均为治疗无效病例,且可能与用药时有肺部感染相关。激素治疗部分有效,死亡率高。
作者 钟巍 张力 王孟昭 李龙芸
机构地区 中国医学科学院中国协和医科大学北京协和医院
出处 《肿瘤学杂志》 CAS 2008年第11期896-898,共3页 Journal of Chinese Oncology
关键词 癌 非小细胞肺 肺疾病 间质性 表皮生长冈子酪氨酸激酶抑制剂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib(ZD1839) (Iressa) tablets[J]. Oncologist, 2003, 8(4):303-306.
  • 2Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib[J]. J Clin Oncol, 2006, 24(16):2549-2556.
  • 3Endo M,Johkoh T, Kimura K, et al. Imaging of gefitinibrelated interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oneology Group [J]. Lung Cancer, 2006, 52(2):135-140.
  • 4Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa)[J]. J Oneol Pharm Pract, 2005, 11(3):127-130.
  • 5Takano T, Ohe Y, Kusumoto M, et al. Risk factors for int erstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib[J]. Lung Cancer, 2004, 45(1): 93- 104.
  • 6Aoe K, Hiraki A, Murakami T, et al. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy[J]. Anticancer Res, 2005, 25(1B):415-418.
  • 7Umemura S, Kishino D, Tabata M, et al. Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer[J]. Intern Med, 2005, 44(9):979-982.
  • 8Kataoka K, Taniguchi H, Hasegawa Y, et al. Interstitial lung disease associated with gefitinib [J]. Respir Med, 2006, 100(4):698-704.
  • 9Kitajima H, Takahashi H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers[J]. Respirology, 2006, 11(2):217-220.
  • 10Sakuma K, Nakamura H, Nakamura T, et al. Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease[J]. Intern Med, 2007, 46(23):1905- 1909.

同被引文献98

  • 1曹淑芳,邓青南,张德明.表皮生长因子受体抑制剂IRESSA致间质性肺炎1例[J].广东药学院学报,2004,20(3):304-305. 被引量：6
  • 2蒋国,洪小南,樊旼,王佳蕾,傅小龙,钱浩,丁琳.吉非替尼(Iressa)治疗手术、放疗、化疗治疗后失败的非小细胞肺癌的初步报告[J].中国肺癌杂志,2004,7(4):305-308. 被引量：45
  • 3崔慧娟,黄琼,陈豫.吉非替尼致间质性肺炎1例[J].临床肿瘤学杂志,2007,12(3):235-236. 被引量：16
  • 4林英城（综述）,林雯（综述）,王鸿彪（综述）,李德锐（审校）.EGFR-TKI治疗非小细胞肺癌研究进展[J].国际肿瘤学杂志,2007,34(6):448-451. 被引量：3
  • 5王洁.EGFRI相关皮肤不良反应中国临床治疗指导原则[N].中国医学论坛报,2008-04-03(B5).
  • 6Reck M,Gatzomeier U.Gefitinib:a new therapy for advanced non-small lung cancer[J].Respir Med,2005,99(3):298-307.
  • 7Sero T,Yamamoto N.Interstitial Lung disease induced by gefitinib in patients with advanced non-small-cell lung cancer,results of a West Japan Thoracic Oncology Group epidrmio logical survey[J].Proc Am soc Clin Oncol,2004,23:629.
  • 8Cohen M H,Williams G A,Sridhara R,et al.FDA drug approval summary:gefitinib (ZD1839) (Iressa) tablets[J].Oncologist,2003,8(4):303-306.
  • 9Ando M,Okamoto I,Yamamoto N,et al.Predictive and survival in non-small-cell lung cancer patients treated with gefitinib[J].Clin Oncol,2006,24(16):2549-2556.
  • 10Takano T,Ohe Y,kusumoto M,et al.Risk factors interstitial Ling disease and predictive factors for tumor response in patients with advanced with gefitinib[J].Lung Cancer,2004,45(1):93-104.

引证文献6

二级引证文献22

肿瘤学杂志
2008年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部